Oncology Centre, Pardubice Regional Hospital, Pardubice, Czech Republic.
Br J Radiol. 2011 Sep;84(1005):850-6. doi: 10.1259/bjr/75446993.
The aim of this study was to analyse the feasibility and determine the benefits of MRI-based pre-planning with CT/MRI data fusion in patients with cervical cancer treated with radical radiotherapy.
Patients underwent MRI examination prior to external beam radiotherapy and prior to the first and fourth fraction of brachytherapy with applicators in place. Insertion of applicators at the radiology department was performed under paracervical anaesthesia. The benefit of MRI pre-planning was determined by comparing conventional treatment planning with dose specification to "point A" and dose specification to 90% of the high-risk clinical target volume (HR-CTV D90). Tolerance of MRI evaluation with applicators, coverage of HR-CTV and dose-volume parameters for organs at risk (OAR) has been assessed in 42 brachytherapy procedures.
Insertion of applicators at the radiology department was successful in all patients and there were no complications. The target dose was higher for MRI planning than for conventional planning (5.3 Gy vs 4.5 Gy). Maximum doses in the bladder and rectum were significantly lower (p<0.05) for MRI planning than for the conventional approach (6.49 Gy vs 7.45 Gy for bladder; 4.57 Gy vs 5.06 Gy for rectum). We found no correlation between the International Commission on Radiation Units (ICRU) point dose for OAR and the maximum dose in OAR. Nevertheless, a strong correlation between the maximum dose in OAR and the minimal dose in a volume of 2 cm(3) has been observed.
MRI-based pre-planning with consecutive CT/MRI data fusion is feasible and safe, with the advantage of increasing the dose to the tumour and decreasing the dose to the organs at risk.
本研究旨在分析在接受根治性放疗的宫颈癌患者中,基于 MRI 的计划前预规划与 CT/MRI 数据融合的可行性并确定其优势。
患者在接受外照射放疗前、近距离放射治疗第 1 次和第 4 次敷贴器插入时进行 MRI 检查。在宫颈旁麻醉下在放射科进行敷贴器插入。通过比较常规治疗计划与“点 A”的剂量规定和 90%高风险临床靶区(HR-CTV D90)的剂量规定,来确定 MRI 计划前预规划的优势。评估了 42 次近距离放射治疗中 MRI 评估与敷贴器覆盖、HR-CTV 覆盖率和危及器官(OAR)剂量体积参数的可耐受情况。
所有患者均在放射科成功插入敷贴器,无并发症发生。MRI 计划的靶区剂量高于常规计划(5.3 Gy 比 4.5 Gy)。与常规方法相比,MRI 计划的膀胱和直肠最大剂量显著降低(p<0.05)(膀胱为 6.49 Gy 比 7.45 Gy;直肠为 4.57 Gy 比 5.06 Gy)。我们未发现 OAR 的国际辐射单位委员会(ICRU)点剂量与 OAR 中的最大剂量之间存在相关性。然而,我们观察到 OAR 中的最大剂量与 2 cm³ 体积中的最小剂量之间存在很强的相关性。
基于 MRI 的计划前预规划与连续 CT/MRI 数据融合是可行且安全的,其优势在于增加肿瘤剂量并降低危及器官剂量。